Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2018.04.99
Abstract: The treatment landscape has changed since the immune checkpoint inhibitors were approved in the treatment of non-small cell lung cancer (NSCLC). Although the promising clinical benefit from programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitors was observed… read more here.
Keywords: immune checkpoint; combination; checkpoint inhibitors; shining light ... See more keywords